Kodiak Sciences is a development-stage biopharmaceutical company based in Palo Alto focused on novel therapeutics for high-prevalence ophthalmic diseases. The company is advancing KSI-301, an anti-VEGF therapy targeting wet age-related macular degeneration and diabetic retinopathy. Led by CEO Victor Perlroth, M.D., Kodiak is using its recent financing to push development of its lead product candidate. The firm completed a mezzanine private financing comprised of convertible notes, indicating a hybrid debt-like instrument. Proceeds from the financing are intended to advance clinical development of KSI-301. No operating metrics such as revenue or user numbers are disclosed in the article. Kodiak Sciences is developing novel biologic therapies targeting retinal diseases and is led by CEO Victor Perlroth, M.D. The company is advancing multiple therapeutic programs focused on wet and dry age-related macular degeneration. Its pipeline highlighted KSI-201, a novel single-agent, multi-inhibitor biologic for wet AMD, and KSI-401, a biologic that blocks activation of the complement system to potentially lessen disease activity in dry AMD patients. Kodiak intends to use the new funds to accelerate existing programs and deepen its retinal pipeline. The company is based in Palo Alto, CA and has raised capital through multiple financings to support its development work.

Total raised

$67M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Apr 2018